Jeantet advises Global Bioenergies on its capital increase in favor of a category of persons with a public offering aimed at retail investors via the Primarybid platform for a total amount of €14.5 million
Paris, on December 17, 2021. Jeantet advised GLOBAL BIOENERGIES, an innovative company working on converting plant-derived resources into isododecane and other compounds used in the cosmetics industry, on its capital increase in favor of a category of persons with a public offering aimed at retail investors via the PrimaryBid platform on Euronext Growth Paris market, for a total of € 14.5 million.
The public offering via the PrimaryBid platform, a British fintech aimed at allowing retail investors to participate in “private placement” transactions under the same conditions as institutional investors, is the second transaction of this type carried out in France.
The subscription period was open from December 13, 2021 after market close to December 14, 2021 before market reopening. The transaction allowed the company to raise around € 14.5 million, including € 1 million via the PrimaryBid platform, through the issuance of 3,510,000 shares at a share subscription price of € 4.13 per share, fixed following an accelerated book building process.
Settlement-delivery of the shares offered and their admission to trading on Euronext Growth Paris market took place on December 16, 2021 (ISIN FR0011052257 / ticker ALGBE).
The capital increase in favor of a category of persons was handled by TP ICAP Midcap, acting as sole lead manager and bookrunner. Within the framework of the PrimaryBid Offering, investors were only able to subscribe for the Offering via the PrimaryBid partners mentioned on the PrimaryBid website (https://primarybid.fr/).
Jeantet (company’s counsel): Cyril Deniaud, partner, and Claire Coquard, associate (Capital Markets law department).